Modality
Radioligand
MOA
CAR-T BCMA
Target
WEE1
Pathway
RNA Splicing
IPFSCLCPAH
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
~Jul 2019
→ ~Oct 2020
Phase 3
Jan 2021
→ Mar 2027
Phase 3Current
NCT07700610
545 pts·IPF
2021-01→TBD·Completed
NCT03114512
517 pts·PAH
2021-11→2027-03·Recruiting
1,062 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-2412mo awayPh3 Readout· PAH
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P3
Complet…
P3
Recruit…
Catalysts
Ph3 Readout
2027-03-24 · 12mo away
PAH
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07700610 | Phase 3 | IPF | Completed | 545 | 6MWD |
| NCT03114512 | Phase 3 | PAH | Recruiting | 517 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA |